CRISPR Therapeutics

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biotechnology company pioneering gene editing therapies using its CRISPR/Cas9 platform. The company develops gene-based medicines for serious diseases, including hemoglobinopathies, oncology, autoimmune, diabetes, and cardiovascular conditions. Its lead product, CASGEVY (exagamglogene autotemcel), is an approved CRISPR/Cas9 gene-edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics also advances CAR T cell therapies and in vivo gene editing programs, and collaborates with partners such as Vertex Pharmaceuticals. Headquartered in Zug, Switzerland, the company serves patients globally.